• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Chosa Oncology

0.79 SEK+5.87 %10.7. klo 18.29
Less than 1K followers

CHOSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+5.87 %
-13.70 %
+2.06 %
-15.08 %
-16.42 %
+32.33 %
-21.27 %
-95.47 %
-93.71 %

Chosa Oncology is a Swedish-Danish biotechnology company that develops solutions for personalized cancer treatment with a focus on diagnostics and drug formulation. The company targets healthcare providers and research actors and works internationally with partners and clinical projects. Chosa Oncology was founded in 2022 and is headquartered in Lund, Sweden.

Read more
Market cap
69.76M SEK
Turnover
13.85K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.8.
2026

Interim report Q2'26

19.11.
2026

Interim report Q3'26

25.2.
2027

Annual report '26

Regulatory press release10.07.2026 klo 09.30

Chosa Oncology AB: CHOSA Oncology appoints US commercialization Bill Cronin with a broad network in the oncology market, to accelerate launch of Platin-DRP

Chosa Oncology
Third party research01.07.2026 klo 11.18

CHOSA Oncology in connection with the TO2 warrant exercise - VH Corp

CHOSA Oncology’s CCO and board member Claus Frisenberg Pedersen visits Västra Hamnen and discusses the latest developments, what benefit CHOSA brings to cancer patients and how the company creates shareholder value. CHOSA is exercising its TO2 warrants...

Chosa Oncology
Press release01.07.2026 klo 11.09

Västra Hamnen Market Focus: CHOSA Oncology in connection with the TO2 warrant exercise

Chosa Oncology

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release01.07.2026 klo 09.30

Chosa Oncology AB: CHOSA Oncology announces commencement of exercise period for TO2 warrants at the fixed price of SEK 0.78

Chosa Oncology
Press release23.06.2026 klo 09.00

Chosa Oncology AB: CHOSA Oncology establishes US presence in Boston to support commercialization of Platin-DRP

Chosa Oncology
Regulatory press release01.06.2026 klo 21.30

Chosa Oncology AB: CHOSA presents data at ASCO validating Platin-DRP on the NanoString platform showing significant overall survival prediction in Phase III lung cancer study

Chosa Oncology
Regulatory press release01.06.2026 klo 21.30

Chosa Oncology AB: CHOSA and AIDA present data at ASCO 2026 showing up to 78% pathological complete response (pCR) rate in breast cancer using combined, integrated, taxane and platinum biomarkers

Chosa Oncology
Regulatory press release27.05.2026 klo 15.40

Bulletin from the annual general meeting on 27 May 2026 in Chosa Oncology AB

Chosa Oncology
Regulatory press release06.05.2026 klo 16.06

Chosa Oncology AB: CHOSA Oncology publishes the Annual and Consolidated Financial Statements for the financial year 2025

Chosa Oncology
Press release27.04.2026 klo 14.00

Chosa Oncology AB: CHOSA Oncology partners with Mount Sinai, New York to test biomarker guiding platin-immunotherapy in lung cancer

Chosa Oncology
Regulatory press release24.04.2026 klo 15.30

Notice of annual general meeting in Chosa Oncology AB

Chosa Oncology
Press release24.04.2026 klo 13.26

Chosa Oncology AB: CHOSA to present new Platin-DRP® data at ASCO 2026

Chosa Oncology
Regulatory press release26.03.2026 klo 14.00

Chosa Oncology AB: CHOSA presents positive data on Platin-DRP® predicting overall survival in advanced NSCLC at the European Lung Cancer Congress 2026

Chosa Oncology
Press release19.03.2026 klo 09.45

Chosa Oncology AB: CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress

Chosa Oncology
Press release23.01.2026 klo 09.33

Chosa Oncology AB: Precision Oncology patent application targeting Platinum Response and Immunotherapy Synergy

Chosa Oncology
Regulatory press release19.01.2026 klo 09.53

Chosa Oncology AB: CHOSA Oncology AB resolves on a directed issue of units of initially approximately SEK 7.3 million

Chosa Oncology
Regulatory press release11.12.2025 klo 15.12

Chosa Oncology AB: CHOSA - The market now doubles for Platin-DRP®, which predicts overall survival in lung cancer patients based on NanoString data

Chosa Oncology
Press release10.11.2025 klo 11.00

Chosa Oncology AB: CHOSA - Platinum chemotherapy is the backbone of PD-1/PD-L1-based lung cancer therapy

Chosa Oncology
Press release20.10.2025 klo 13.00

Chosa Oncology AB: CHOSA's presented data on the carboplatin response predictor in breast cancer patients on the ESMO conference

Chosa Oncology
Press release07.10.2025 klo 16.28

Chosa Oncology AB: CHOSA Wins 2025 Jiangning International Entrepreneurship Contest (Greater Shanghai region), China

Chosa Oncology